Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

Molecular Pharmaceutics

Volumn 9, Issue 11, 2012, Pages 3236-3245

  Durmus, Selvi ^a   Sparidans, Rolf W ^b   Wagenaar, Els ^a   Beijnen, Jos H ^b,c   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

ABC transporters; B RAFV600E; blood?brain barrier; brain metastasis; elacridar; melanoma; oral availability; vemurafenib

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN 1; VEMURAFENIB;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TRANSPORT; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACRIDINES; ADMINISTRATION, ORAL; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DRUG COMBINATIONS; FEMALE; HUMANS; INDOLES; KIDNEY; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; SULFONAMIDES; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION;

EID: 84868556980     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3003144     Document Type: Article

References (32)

1. Lee, S. M.; Betticher, D. C.; Thatcher, N. Melanoma: chemotherapy Br. Med. Bull. 1995, 51 (3) 609-630
2. Garbe, C.; Eigentler, T. K.; Keilholz, U.; Hauschild, A.; Kirkwood, J. M. Systematic review of medical treatment in melanoma: current status and future prospects Oncologist 2011, 16 (1) 5-24
3. Ascierto, P. A.; Kirkwood, J. M.; Grob, J. J.; Simeone, E.; Grimaldi, A. M.; Maio, M.; Palmieri, G.; Testori, A.; Marincola, F. M.; Mozzillo, N. The role of BRAF V600 mutation in melanoma J. Transl. Med. 2012, 10 (1) 85
4. Lemech, C.; Arkenau, H. T. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities Clin. Med. Insights Oncol. 2012, 6, 53-66
5. Verschraegen, C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma Cancer Manage. Res. 2012, 4, 1-8
6. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer Nature 2002, 417 (6892) 949-954
7. FDA approves vemurafenib for treatment of metastatic melanoma. Oncology (Williston Park) 2011, 25 (10), 906.
8. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; ODay, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011, 364 (26) 2507-2516
9. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; ODwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 2010, 363 (9) 809-819
10. Skibber, J. M.; Soong, S. J.; Austin, L.; Balch, C. M.; Sawaya, R. E. Cranial irradiation after surgical excision of brain metastases in melanoma patients Ann. Surg. Oncol. 1996, 3 (2) 118-123
11. Sampson, J. H.; Carter, J. H., Jr.; Friedman, A. H.; Seigler, H. F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J. Neurosurg. 1998, 88 (1) 11-20
12. Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J. Pharmacol. Exp. Ther. 2010, 333 (3) 788-796
13. Lagas, J. S.; Sparidans, R. W.; van Waterschoot, R. A.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin Antimicrob. Agents Chemother. 2008, 52 (3) 1034-1039
14. Lagas, J. S.; van Waterschoot, R. A.; van Tilburg, V. A.; Hillebrand, M. J.; Lankheet, N.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment Clin. Cancer Res. 2009, 15 (7) 2344-2351
15. Lagas, J. S.; van Waterschoot, R. A.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation Mol. Cancer Ther. 2010, 9 (2) 319-326
16. Shukla, S.; Chen, Z. S.; Ambudkar, S. V. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance Drug Resist. Updates 2012, 15 (1-2) 70-80
17. Tang, S. C.; Lagas, J. S.; Lankheet, N. A.; Poller, B.; Hillebrand, M. J.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 2012, 130 (1) 223-233
18. Tang, S. C.; Lankheet, N. A.; Poller, B.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib J. Pharmacol. Exp. Ther. 2012, 341 (1) 164-173
19. Lockman, P. R.; Mittapalli, R. K.; Taskar, K. S.; Rudraraju, V.; Gril, B.; Bohn, K. A.; Adkins, C. E.; Roberts, A.; Thorsheim, H. R.; Gaasch, J. A.; Huang, S.; Palmieri, D.; Steeg, P. S.; Smith, Q. R. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin. Cancer Res. 2010, 16 (23) 5664-5678
20. Sparidans, R. W.; Durmus, S.; Schinkel, A. H.; Schellens, J. H.; Beijnen, J. H. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2012, 889-890, 144-147
21. Bakos, E.; Evers, R.; Szakacs, G.; Tusnady, G. E.; Welker, E.; Szabo, K.; de, H. M.; van, D. L.; Borst, P.; Varadi, A.; Sarkadi, B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain J. Biol. Chem. 1998, 273 (48) 32167-32175
22. Jonker, J. W.; Buitelaar, M.; Wagenaar, E.; Van Der Valk, M. A.; Scheffer, G. L.; Scheper, R. J.; Plosch, T.; Kuipers, F.; Elferink, R. P.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (24) 15649-15654
23. Pavek, P.; Merino, G.; Wagenaar, E.; Bolscher, E.; Novotna, M.; Jonker, J. W.; Schinkel, A. H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine J. Pharmacol. Exp. Ther. 2005, 312 (1) 144-152
24. Poller, B.; Wagenaar, E.; Tang, S. C.; Schinkel, A. H. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier Mol. Pharmaceutics 2011, 8 (2) 571-582
25. Zimmermann, C.; van de Wetering, K.; van de Steeg, E.; Wagenaar, E.; Vens, C.; Schinkel, A. H. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2) Drug Metab. Dispos. 2008, 36 (4) 631-640
26. Mittapalli, R. K.; Vaidhyanathan, S.; Sane, R.; Elmquist, W. F. Impact of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a novel B-RAF Inhibitor: Vemurafenib (PLX4032) J. Pharmacol. Exp. Ther. 2012, 342 (1) 33-40
27. Agarwal, S.; Uchida, Y.; Mittapalli, R. K.; Sane, R.; Terasaki, T.; Elmquist, W. F. Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice Drug Metab. Dispos. 2012, 40 (6) 1164-1169
28. Agarwal, S.; Sane, R.; Gallardo, J. L.; Ohlfest, J. R.; Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux J. Pharmacol. Exp. Ther. 2010, 334 (1) 147-155
29. Polli, J. W.; Olson, K. L.; Chism, J. P.; John-Williams, L. S.; Yeager, R. L.; Woodard, S. M.; Otto, V.; Castellino, S.; Demby, V. E. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino }methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab. Dispos. 2009, 37 (2) 439-442
30. Zhou, L.; Schmidt, K.; Nelson, F. R.; Zelesky, V.; Troutman, M. D.; Feng, B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice Drug Metab. Dispos. 2009, 37 (5) 946-955
31. Agarwal, S.; Elmquist, W. F. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance Mol. Pharmaceutics 2012, 9 (3) 678-684
32. de Vries, N. A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J. H.; van, T. O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan Clin. Cancer Res. 2007, 13 (21) 6440-6449